Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Xenon ( (XENE) ).
On January 17, 2025, Christopher Von Seggern stepped down as Chief Commercial Officer of Xenon Pharmaceuticals Inc. and departed from the company. In connection with his departure, Von Seggern signed a Separation Agreement receiving severance and benefits as per his original offer letter, as well as a 2024 annual bonus. Additionally, he will act as a consultant for the company until May 1, 2025, during which time his equity awards will continue to vest, with the exercise period extending until August 1, 2025.
More about Xenon
Xenon Pharmaceuticals Inc. operates in the pharmaceutical industry, focusing on developing innovative therapeutics to address neurological disorders.
YTD Price Performance: -1.37%
Average Trading Volume: 400,014
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $3.02B
For detailed information about XENE stock, go to TipRanks’ Stock Analysis page.